Abstract: A posterior upright of an ankle foot orthosis with adjustable degree of bending. A posterior upright 4 of an ankle foot orthosis 1 is provided between a heel posterior portion of a footrest portion 2 on which a foot portion is placed and a lower leg mounting portion 3 mounted on a lower leg portion below a knee. In the posterior upright 4, a plurality of FRP sheets 5a to 5c are laminated, and an upper end portion and a lower end portion of the FRP sheets are joined by heat sealing. An upper end portion 4A is a portion connected to the lower leg mounting portion 3 and a lower end portion 4B is connected to the footrest portion 2. An intermediate portion between the upper end portion 4A and the lower end portion 4B has +gaps S1 and S2 between the FRP sheets 5a to 5c.

Abstract: The subject of the present invention is to provide means to fully achieve the inhibition of cancer bone metastasis, which was accomplished through the repeated selection of agents with aiming at obtaining more beneficial effects on the inhibition of cancer bone metastasis. The invention is achieved by combining an inhibition substance of the activation of osteoclast caused by the degradation of a signaling molecule, TRAF6, in the activation of osteoclast, a suppressive substance of the differentiation from osteoclast precursor cells to mature osteoclasts, and/or a bone resorption inhibitor and/or a Cox2 synthesis inhibitor. This combination was found to have an extremely high utility for the inhibition of cancer bone metastasis.

Abstract: There is provided means for increasing complete remission rates and shortening a period to complete remission and for achieving a synergistic effect with immunotherapy that is directed at bringing about enhanced effects from molecule-targeting therapeutic drugs. More specifically, an object is to achieve a synergistic effect by combining use of a novel immunotherapy for cancer that focuses on CTL activity, NKT activity, NK activity and ?VEGF and the like, and molecule-targeting therapeutic drugs, particularly tyrosine kinase inhibitors. The present invention was accomplished based on the finding that combined use of a tyrosine kinase inhibitor and an IL-12 inducer achieves a superior synergistic effect in cancer therapy.

Abstract: A therapeutic agent for a cancer comprising a therapeutically effective amount of an active ingredient, wherein the therapeutic agent is used referring to an ability of acting on NK cell antigen receptor NKR-P1 of NKT cell as an index of the ability to activate the NKT cell.

Abstract: A therapeutic agent for a cancer comprising a therapeutically effective amount of an active ingredient, wherein the therapeutic agent is used referring to an ability of acting on NK cell antigen receptor NKR-P1 of NKT cell as an index of the ability to activate the NKT cell.